No. 52 / 28 August 2026

To: BUCHAREST STOCK EXCHANGE
FINANCIAL SUPERVISORY AUTHORITY

ANNOUNCEMENT

Report Date: **28 August 2026**
Name of the issuing company: **MED LIFE S.A. ("MedLife" or "the Company")**
Registered Office: **Bucharest, 365 Calea Grivitei, district 1, Romania**
Telephone / Fax number: **0374 180 470**
Unique Registration Code at the National Office of Trade Registry: **8422035**
Order number on the Trade Registry: **J1996003709402**
EUID: **ROONRC.J1996003709402**
Subscribed and paid-in share capital: **RON 132,870,492**
Total number of shares: **531,481,968 (out of which 665,983 shares without voting rights and 530,815,985 shares with voting rights)**
Regulated market on which the issued securities are traded: **Bucharest Stock Exchange, Premium Category**

MedLife closes the first half of the year with robust 10% YoY growth in pro-forma consolidated revenue, alongside improved margins

- *MedLife recorded pro-forma consolidated revenue of RON 1.7 billion in H1 2026, up 10% compared with H1 2025, while the pro forma EBITDA margin improved YoY.*
- *The Group reported significant growth across most business lines, with the strongest performances recorded by the corporate, clinics, and laboratories divisions, which posted revenue growth of 17%, 15%, and 13%, respectively.*
- *As a leader in technology and innovation, MedLife is accelerating the development of strategic projects focused on personalized medicine. The company is set to launch a new version of its app, which will integrate genetic and biometric data, microbiome information, and medical history into a single digital ecosystem, in order to provide recommendations based on each patient's individual profile.*
- *This is the first time in the region that a healthcare operator has brought together advanced technologies, medical data, and lifestyle data to develop proprietary models and deliver a personalized approach for each individual.*
- *Alongside these strategic initiatives, MedLife continues to pursue new acquisition and development opportunities to strengthen its position as a market leader in Romania and a top regional player.*

Bucharest, August 28th, 2026: MedLife, the leader of Romania's private healthcare services market and the only Romanian-owned company among the top private healthcare operators listed on the Bucharest Stock Exchange, announces its financial results for the first half of 2026, marking continued progress in the company's operational performance.

In the first half of the year, the MedLife Group recorded robust 10% growth in pro forma consolidated revenue compared with the same period in 2025, reaching RON 1.7 billion. In terms of profitability, the pro forma EBITDA margin reached 16.4%, an improvement over the same period last year, supported by the upward trend recorded in the second quarter. The results reflect solid performance across most business lines, driven by robust volume growth, as well as by measures aimed at improving efficiency and optimizing costs across the Group.

The strongest growth rates were recorded by the corporate segment (17%), clinics (15%), laboratories (13%), and hospitals (8%). The Corporate division stands out for its accelerated growth compared with the previous year, supported by the expansion of its customer portfolio and the diversification of solutions offered. The performance of this segment contributes to strengthening the company's market share and reflects MedLife's ability to develop, in real time, new products tailored to the continuously evolving needs of employees and employers.

At the same time, the growth of the laboratories division is underpinned by the expansion of its advanced diagnostic services portfolio, including DNA testing, oncogenetics, and, more recently, microbiome analysis — state-of-the-art solutions that support the company's strategic focus on personalized medicine.

"The first six months of the year confirm the consistent growth of the MedLife Group, supported by increases across most business lines, robust patient volumes, and ongoing strategic projects with long-term impact, despite the fragile macroeconomic situation and declines in consumer markets. We continue to focus on developing our ongoing projects and are well-positioned to maintain our growth momentum in the coming period. At the same time, we remain attentive to small- and medium-sized acquisition opportunities, both domestically and abroad" said **Mihai Marcu, President and CEO of MedLife Group**.

Strategic investments in the development of personalized medicine

Alongside the development of its core business lines, MedLife focused in the first half of the year on accelerating strategic projects that combine innovation and cutting-edge technology, making significant progress towards personalized medicine. The development of the Longevity 100+ program and the mobile app are two of the company’s key objectives, in line with its ongoing investments in research and development.

"After opening a new chapter in personalized medicine last year—as the first company in the country and the region to sequence the human genome using our own resources—one of our priorities in the first half of 2026 was the development of the Longevity 100+ program. The fact that we were able to offer, for the first time in Romania, large-scale low-pass genetic testing represents an important step toward democratizing access to genetic information and bringing precision medicine closer to patients. We have also expanded the Longevity 100+ program by integrating microbiome analysis—another first at the national level. MedLife is the only company in Romania that currently has the capacity to fully sequence the human microbiome within the country. Thus, by correlating genetic information with microbiome data, we can gain a broader and more nuanced perspective on each patient’s health.

“We believe that the true value of these achievements becomes apparent when we are able to take a holistic view of genetic predisposition, the microbiome, medical data, and lifestyle, in order to identify risks earlier and to provide recommendations that are as relevant as possible for each individual patient", **added Mihail Marcu, CEO & Chairman of the Board of MedLife Group**.

H2 outlook: digitalization, ai, and advanced technologies to address the needs of tomorrow’s patients

In the coming period, MedLife will continue to pursue its strategic projects, maintaining its focus on innovation, AI, digitalization, and the development of medical solutions tailored to patients’ continuously evolving needs.

The company aims to accelerate the transition to personalized medicine by continuing to develop the Longevity 100+ program and the mobile app, with the goal of building a digital infrastructure capable of supporting the next generation of preventive healthcare services. According to company representatives, this fall the MedLife app will evolve from a tool for scheduling and accessing medical services into a digital health companion, capable of integrating multiple types of medical data into a single ecosystem and providing personalized recommendations based on each patient’s individual profile. In the first phase, the app will consolidate medical test histories, medical record data, family history, biometric information, and the results of the Longevity 100+ genetic test; in subsequent phases, other types of data—such as imaging studies, psychometric assessments, and information on the microbiome and nutrition—will be progressively integrated.

In parallel with the implementation of strategic projects, MedLife representatives will continue to focus on streamlining operations and reducing costs to improve performance and support margin growth, while simultaneously reducing debt levels and improving the Net Debt/EBITDA ratio.

“Medicine is evolving at an unprecedented pace, and we want to be at the forefront of this transformation. We have the resources, infrastructure, and expertise needed to contribute to the development of personalized medicine and bring the benefits of new technologies closer to patients. At the same time, we remain disciplined in our capital allocation, attentive to acquisition opportunities that can accelerate the Group’s growth, and focused on improving operational performance. Our goal is to continue growing steadily and to strengthen our position, both in Romania and regionally,” **concluded Mihai Marcu, CEO & Chairman of the Board of MedLife Group.**

Analysis of the Consolidated Comprehensive Income

Sales for the 6-month period ended June 30, 2026, amounted to RON 1,738,986,990 higher by 10.5% compared to sales recorded in the first 6 months of 2025. The increase was mainly the result of growth in almost all of the Group's business lines, as well as the impact of the acquisitions completed by the Group in 2025 and 2026.

Operating expenses include fixed and variable costs, as well as the cost of goods and materials used by the Group to provide services. The Group recorded operating expenses of RON 1,658,894,792 for the 6-month period ended June 30, 2026, representing an increase of 10.9%, or RON 162,564,117 as compared to the similar period of 2025. The Group's operating expenses as a percentage of total operating income represented 95.06% for 6 months 2026 and 94.67% for 6 months 2025.

Other administration and operating expenses include an amount of RON 7,828,160 paid during the period in connection with the final resolution of a litigation involving the Company. No provision had been recognised in prior reporting periods in respect of this litigation, as, based on the information available at the respective reporting dates, including the developments in the proceedings and the decisions previously issued by the competent authorities, management assessed that the recognition criteria for a provision under IAS 37 were not met. Following the final outcome of the litigation, the related amount was recognised in full in the current reporting period.

Operating profit increased by 2.3% in the 6-month period of 2026 compared to the same period of 2025, from RON 84,307,467 in 2025 to RON 86,257,266 in 2026.

Financial losses increased by RON 26,180,582 in the 6-month period of 2026, from a loss of RON 83,407,939 as of June 30, 2025, to a loss of RON 109,588,521 as of June 30, 2026, mainly due to the depreciation of the RON against the EUR, which resulted in higher foreign exchange losses related to the Group's EUR-denominated borrowings.

The net result for the 6-month period ended June 30, 2026 decreased with RON 23,803,232 compared to the corresponding period of 2025, from RON 10,885,945 for the 6-month period of 2025 to RON 34,689,177 for 6-month period of 2026.

Analysis of the Consolidated Balance Sheet

Non-current assets amount to RON 2,589,611,238 as of June 30, 2026, registering an increase of RON 31,572,691, or 1.2%, compared to December 31, 2025. The increase was mainly due to increase in goodwill with 27,441,210 RON following the acquisition of Medstar SRL.

Current assets increased by RON 67,552,187, or 9.6%, from RON 702,888,150 as of December 31, 2025 to RON 770,440,337 as of June 30, 2026.

Current liabilities (excluding interest-bearing items) increased by RON 47,805,307, or 7%, from RON 662,703,593 as of December 31, 2025 to RON 710,508,900 as of June 30, 2026.

Interest-bearing debt increased by RON 92,414,344, or 5%, from RON 1,931,339,624 as of December 31, 2025 to RON 2,023,753,968 as of June 30, 2026.

Operational Key Performance Indicators

Business line	Info	6 months ended	
		2026	**2025**
Clinics	**Revenue**	**674,992,716**	**586,623,201**
	Visits	2,662,268	2,378,931
	Avg fee	253.5	246.6
Hospitals	**Revenue**	**473,904,667**	**437,787,015**
	Patients	109,202	104,393
	Avg fee	4,339.7	4,193.6
Laboratories	**Revenue**	**194,559,115**	**172,789,754**
	Analyses	5,920,767	5,241,532
	Avg fee	32.9	33.0
Corporate	**Revenue**	**175,640,933**	**150,267,854**

	Subscriptions	999,018	887,962
	Avg fee	188.8	169.2
Dentistry	**Revenue**	**59,593,514**	**61,989,558**
	Visits	90,138	89,719
	Avg fee	661.1	690.9
Pharmacies	**Revenue**	**50,462,145**	**37,735,631**
	Clients	244,597	221,159
	Sales per client	206.3	170.6
Others	**Revenue**	**109,833,899**	**126,763,992**
Total		**1,738,986,990**	**1,573,957,005**

Report availability

The H1 2026 results report is available on the company's website, in the Investor Relations section / Reports and Presentations / Financial Reports (https://www.medlife.ro/investor-relations/reports-and-presentations/financial-reports) and on the Bucharest Stock Exchange's website (symbol **M**).

Results presentation conference call

We remind you that MedLife will hold a conference call for analysts and investors to present the financial results, on 28 August 2026, starting 4:00 p.m. (Romanian time). The conference call will be held in English, and the transcript will be available afterwards, on MedLife's website, in the Investor Relations section / Reports and Presentations / Financial Reports. In order to participate to the event, please contact us at investors@medlife.ro.

Mihail Marcu
Chief Executive Officer

Ioana Birsu
Investor Relations Manager